SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas expected Q4 2026 Phase 3 topline results for HLP003, its investigational add-on treatment for major depressive disorder. Traders are split between optimism that the readout could validate the program and concerns about trial uncertainty, potential dilution, and volatility around the binary catalyst.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody candidate for menopausal hot flashes, and its Phase 1/2 data presentation at a menopause conference; traders are looking for added evidence on efficacy, durability and safety after encouraging Phase 2 topline results. Bulls see the data as a potential validation of the companys internal pipeline, while skeptics question whether the presentation adds enough beyond known results and warn that expectations and recent volatility may set up a sell-the-news reaction.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Renewed, unconfirmed takeover chatter around a possible offer from an unidentified West Coast technology company is dominating discussion, with traders speculating about buyers such as Meta while others caution that no bid has been confirmed. Upcoming earnings and concerns about transaction margins are also in focus, but the takeover speculation is driving much of the debate.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is drawing attention amid a steep, prolonged selloff, with traders citing weakness across Chinese EV stocks, concerns about demand, profitability and analyst downgrades. Bulls counter that delivery growth, European expansion and AI-chip and robotics initiatives could support the business, while frustrated holders question whether those developments can improve shareholder returns.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons rally to record highs is drawing attention amid rising crude prices tied to Middle East supply tensions and anticipation of its upcoming quarterly report, with traders also citing stronger refining margins. The conversation is broadly bullish, though some caution that the stock is extended and that oil-price swings or earnings expectations could reverse the move.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Keytruda showed a 42% reduction in recurrence or death risk, but shares sold off as traders judged the outcome against high expectations after a major run-up. The community is split between viewing the data as strong validation of the cancer-vaccine platform and questioning whether the benefit, individualized manufacturing, and commercialization prospects justify the valuation.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak quarterly results, sharply reduced full-year outlook and suspended dividend are driving attention, alongside managements warning of recession-level appliance demand and its attribution of the downturn partly to the Iran war. Traders are debating whether the selloff reflects severe financial and management problems or an overreaction that could create a contrarian buying opportunity; no article was provided that directly supports the catalyst.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is drawing attention amid concern about a broad-market pullback, with traders citing rising Treasury yields, persistent inflation and possible Fed rate hikes, alongside geopolitical and energy-market risks. The community is split between recession and crash warnings and investors viewing any dip as a buying opportunity or continuing to favor long-term index investing.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins sharp weekend selloff and break below a widely watched support level dominate discussion, with traders focused on whether further technical support will hold and pointing to leveraged long liquidations and thin weekend trading. Bearish calls for more downside compete with dip-buying and bear-trap arguments, while some traders blame manipulation without clear evidence.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is drawing attention ahead of its earnings report and investor day, with traders also watching hyperscaler results for clues about AI infrastructure demand. The community is divided between expecting strong results and continued growth, and worrying that the broader AI-stock selloff and valuation reset could outweigh solid company fundamentals.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?

Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat 

Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential. 

Healthcare ETFs to Buy as UnitedHealth Beats on Q3 Earnings

UnitedHealth's Q3 earnings beat estimates, lifting shares 6.3%. Explore three healthcare ETFs offering UNH exposure while diversifying Medicaid risks. 

Bet on These Healthcare ETFs to Benefit From the Aging US Population

With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB

Key PointsThe Vanguard Health Care ETF offers a broad healthcare focus with a significantly lower expense ratio of 0.09% compared to its peer...

Consumer Sentiment Drops in September: ETFs to Consider

Consumer sentiment falls to a four-month low amid persistent inflation and uncertainty. Here are some ETFs that investors may consider.

MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near

Equity

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.


Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ?

Key PointsThe Vanguard Health Care ETF (VHT) is significantly cheaper to own than the iShares Global Healthcare ETF (IXJ...

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

Key PointsVanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF...

Vanguard World Fund - Vanguard Health Care ETF

Bearish Sentiment

<ul class="summary-bullets"><li>MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa.&nbsp;</li><li>By late November, the FDA should say whether it accepted the filing, whether it will review it faster, and when it will decide.</li><li>Three shots are already approved for HS: AbbVie’s Humira, Novartis’s Cosentyx, and UCB’s Bimzelx.</li></ul><p>Shares of MoonLake Immunotherapeutics (MLTX) slid about 15% this week as investors marked down the stock weeks before a planned U.S. filing for its lead drug.</p><p>MLTX &nbsp;has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock about 80% below its 52-week high. The stock is on track to clock its worst week in about a year, if losses hold.</p><h2 class="st-heading-2">Filing Date Looms</h2><p>MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa, a painful condition that causes boils and tunnels under the skin. The request would cover both adults and teens. The agency has already said the existing studies can support a filing.</p><p>By late November, the FDA should say whether it accepted the file, whether it will review it faster, and when it will decide. A standard review would point to a possible U.S. launch in the second half of 2027.</p><h2 class="st-heading-2">What The Drug Did In Trials</h2><p>Sonelokimab is an experimental injection that blocks two proteins that drive inflammation. After one year in two late-stage studies, about two-thirds of adults had a large drop in skin lesions and about one-third saw their lesions disappear. Early data in teens looked similar. Safety matched earlier studies.</p><p>Doubt remains because the first look at the data, at four months, was mixed. One study succeeded. The second missed its main goal after patients on dummy treatment improved more than expected, a setback that crushed the stock a year ago. The FDA, however, later said MoonLake did not need new skin-disease trials.</p><p>In August, a late-stage study of the drug in patients with psoriatic arthritis also hit its main goal.</p><h2 class="st-heading-2">A Crowded Market</h2><p>Three shots are already approved for HS: AbbVie’s Humira, Novartis’s Cosentyx, and UCB’s Bimzelx. Other new drugs are also in development.</p><p>MoonLake says its drug design and long-term trial results can help it stand out, but it would enter a market where rivals already have years of real-world use.</p><h2 class="st-heading-2">Next Catalysts</h2><p>MoonLake ended June with $537 million in cash, enough, it says, to last into mid-2028. It has no approved product and lost $131.5 million in the first half of 2026.</p><p>The nearest catalyst for the stock is the hidradenitis filing. A second late-stage joint-disease study should finish enrolling this quarter, with results later this year. MoonLake also plans to start a late-stage trial in palmoplantar pustulosis, which has no approved U.S. treatment.</p><h2 class="st-heading-2">How Did MLTX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around MLTX stock stayed ‘neutral’ over the past 24 hours, while message volume was ‘high.’</p><p>A Stocktwits user said that shorts are resorting to bashing the company for its perceived lack of announcements, as they have no arguments against its drug.</p><p><stembedurl>https://stocktwits.com/Modern_portholio_theory/message/664081954</stembedurl></p><p>Another user opined that even with approval for sonelokimab, the company will enter a crowded market. “Yes the pie is big but it will &nbsp;be divided into many little pieces. $20 is already a lot for this company,” they wrote.</p><p><stembedurl>https://stocktwits.com/Antocar/message/664076232</stembedurl></p><p>Certain analysts, however, are more bullish. Last month, H.C. Wainwright raised the firm's price target on MoonLake Immunotherapeutics to $50 from $45 and kept a Buy rating on the shares after increasing its probabilities of approval to 70% from 60% in hidradenitis suppurativa, to 60% from 50% in psoriatic arthritis, and to 50% from 40% in axial spondyloarthritis.</p><p><a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has fallen 3% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dell-hpe-stocks-lead-s-and-p-500-gains-oracle-s-95-b-capex-plan-lifts-ai-stocks/cZtXFJxRBb2">DELL, HPE Stocks Lead S&amp;P 500 Gains: Oracle’s $95B Capex Plan Lifts AI Stocks</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.

MoonLake Immunotherapeutics

T Rowe Price Capital Appreciation Equity ETF

Vanguard Health Care ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

VHT Vanguard Health Care ETF

Fundamentals

Latest VHT News